RB1 and breast cancer: Our CRISPR screen identified that drivers of ERα signaling remained essential for the viability of ER+ breast cancer cells irrespective of RB1 status (Fig. 2B), suggesting that ER+/RB-deficient breast cancer cells may still be dependent on ERα signaling.